Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Current best practice for bladder cancer: a narrative review of diagnostics and treatments
Éva Compérat, Mahul B. Amin, Richard Cathomas, et al.
The Lancet (2022) Vol. 400, Iss. 10364, pp. 1712-1721
Open Access | Times Cited: 211

Showing 76-100 of 211 citing articles:

The Diagnostic and Therapeutic Role of snoRNA and lincRNA in Bladder Cancer
Hao Wang, Yanfei Feng, Xiangyi Zheng, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1007-1007
Open Access | Times Cited: 8
MTX-211 Inhibits GSH Synthesis through Keap1/NRF2/GCLM Axis and Exerts Antitumor Effects in Bladder Cancer
Bing Hu, Ru Chen, Ming Jiang, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7608-7608
Open Access | Times Cited: 8
circKDM1A suppresses bladder cancer progression by sponging miR-889-3p/CPEB3 and stabilizing p53 mRNA
Haotian Chen, Jing Wen, Wentao Zhang, et al.
iScience (2024) Vol. 27, Iss. 4, pp. 109624-109624
Open Access | Times Cited: 2
Chest wall tumor following intravesical BCG instillation for non-muscle invasive bladder cancer
Marc Hartert, C Deppe, Ludger Fink, et al.
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases (2024) Vol. 35, pp. 100438-100438
Open Access | Times Cited: 2
Study on the Role and Mechanism of SLC3A2 in Tumor-Associated Macrophage Polarization and Bladder Cancer Cells Growth
Pei‐Shan Wu, Lingna Zhao, Guangqi Kong, et al.
Technology in Cancer Research & Treatment (2024) Vol. 23
Open Access | Times Cited: 2
Nuclear matrix protein 22 in bladder cancer
Kun Cheng, Shun Wan, Siyu Chen, et al.
Clinica Chimica Acta (2024) Vol. 560, pp. 119718-119718
Closed Access | Times Cited: 2
Targeting Nrf2 signaling pathways in the role of bladder cancer: From signal network to targeted therapy
Liang Wu, Hu Zhao, Xiao-fen Song, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 176, pp. 116829-116829
Open Access | Times Cited: 2
Integrated analysis of multiple transcriptomic approaches and machine learning integration algorithms reveals high endothelial venules as a prognostic immune-related biomarker in bladder cancer
Jinge Zhang, Yuan Huang, Xing Tan, et al.
International Immunopharmacology (2024) Vol. 136, pp. 112184-112184
Closed Access | Times Cited: 2
Consistencies in Follow-up After Radical Cystectomy for Bladder Cancer: A Framework Based on Expert Practices Collaboratively Developed by the European Association of Urology Bladder Cancer Guideline Panels
Laura S. Mertens, H.M. Bruins, Roberto Contieri, et al.
European Urology Oncology (2024)
Closed Access | Times Cited: 2
Cuproptosis and Cuproptosis‐Based Synergistic Therapy for Cancer Treatment
Zhiyang Shen, Yu Qiu, Haizhen Ding, et al.
ChemMedChem (2024) Vol. 19, Iss. 21
Closed Access | Times Cited: 2
The Role of Long Non-Coding RNF144A-AS1 in Cancer Progression
Wei Wu, Xiaolan Li, Xueqing Li, et al.
Cell Biochemistry and Biophysics (2024) Vol. 82, Iss. 3, pp. 2007-2017
Closed Access | Times Cited: 2
GAS6-AS1 drives bladder cancer progression by increasing MMP7 expression in a ceRNA- and RBP-dependent manner
Xinyi Zhou, Linmei Xiao, Fanyu Meng, et al.
Translational Oncology (2024) Vol. 48, pp. 102065-102065
Closed Access | Times Cited: 2
SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis
Jingcheng Zhang, Wentao Zhang, Liu Ji, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 2
Developing a Novel Prognostic Model Based on Muscle-Invasive Bladder Cancer Types: A Multicenter Retrospective Cohort Study of Patients Who Received Radical Cystectomy and Chemotherapy
Shicong Lai, Jianyong Liu, Haopu Hu, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 13, pp. 8967-8977
Closed Access | Times Cited: 2
ASO Author Refections: A Novel Prognostic Model Based on Muscle-Invasive Bladder Cancer Types
Shicong Lai, Jianyong Liu, Guan Zhang, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 13, pp. 9004-9005
Closed Access | Times Cited: 2
Trimodal Therapy in the Treatment of Muscle-Invasive Bladder Cancer
Yongsoo Jo, Hyeong Dong Yuk
Journal of Urologic Oncology (2024) Vol. 22, Iss. 3, pp. 256-267
Closed Access | Times Cited: 2
Associations of dietary isothiocyanate exposure from cruciferous vegetable consumption with recurrence and progression of non–muscle-invasive bladder cancer: findings from the Be-Well Study
Zinian Wang, Marilyn L. Kwan, Reina Haque, et al.
American Journal of Clinical Nutrition (2023) Vol. 117, Iss. 6, pp. 1110-1120
Closed Access | Times Cited: 5
Development and validation of a disulfidptosis and M2 TAM-related classifier for bladder cancer to explore tumor subtypes, immune landscape and drug treatment
Congzhe Ren, Qihua Wang, Zhunan Xu, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 17, pp. 15805-15818
Closed Access | Times Cited: 5
Molecular map of cGAS-STING pathway-related genes in bladder cancer: the perspective toward immune microenvironment and prognosis
Wei Dong, Ying Liu, Ying Yuan, et al.
Aging (2024)
Open Access | Times Cited: 1
Curcumin Inhibits Bladder Cancer by Inhibiting Invasion via AKT/MMP14 Pathway
Kai Wang, Wen Xiao, Qi Zeng
Discovery Medicine (2024) Vol. 36, Iss. 180, pp. 71-71
Open Access | Times Cited: 1
Independent prognostic value of CLDN6 in bladder cancer based on M2 macrophages related signature
Da Qi, Yan Lu, Huinan Qu, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109138-109138
Open Access | Times Cited: 1
Molecular profiling of a bladder cancer with very high tumour mutational burden
Manuel Scimeca, Julia Bischof, Rita Bonfiglio, et al.
Cell Death Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 1
Strategically Staged Tumor Ablation and Inflammation Suppression Using Shell‐Core Nanoparticles to Eradicate Bladder Tumors and Prevent Recurrence
Yong Xu, Ruiyun Zhang, Junjie Zhu, et al.
Advanced Functional Materials (2024) Vol. 34, Iss. 37
Closed Access | Times Cited: 1
CRISPR-based gene expression platform for precise regulation of bladder cancer
Tianying Zhan, Xiao Li, Jiumin Liu, et al.
Cellular & Molecular Biology Letters (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 1
Biological functions and therapeutic potential of SRY related high mobility group box 5 in human cancer
Juan-di Xue, Wan-fang Xiang, Mingqin Cai, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1

Scroll to top